NCT03258320RecruitingPhase 2/3
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
A Phase II-III Study of Neoadjuvant Chemotherapy Involving Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Followed by Surgery for Patients With High Risk Prostate Cancer
Source: ClinicalTrials.gov · Last updated 12 Jan 2026
Brief summary (registry, in English)
Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatment with neoadjuvant chemotherapy before radical prostatectomy may better control the tumor before it has the chance to convert into the disease of castration-resistant prostate cancer (CRPC), which is finally refractory to most modalities of clinical intervention with a clinically lethal nature.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 20 Aug 2017
- Start date
- 1 Jan 2015
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Shanghai Jiao Tong University School of Medicine
- Diseases
- Prostate cancer
- NCT number
- NCT03258320
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 300
- From 1 Jan 2015 to the primary completion date, 31 Dec 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- prior cancer chemotherapy
Age
- age ≥ 76
Other
- severe major organ dysfunction
- WHO performance status of \>1
- Stage IV.
Who the study is looking for
- 40 ≤ age ≤ 75 years with histologically proven PCa
- no severe major organ dysfunction
- WHO performance status of 0 or 1
- no prior cancer chemotherapy
- A Clinical Stage ≥ T2c (T2c, N0, M0) of prostate cancer but ideally without diagnosed distant metastasis (according to the 2016 American Joint Committee on Cancer (AJCC) definition of TNM staging system, Staging Manual, Eighth Edition) as determined by a preoperative evaluation that included a pleural computed tomography (CT) scan.
Age in the registry: 40 years to 75 years · Sex: Male · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Qilu Hospital of Shandong University Coordinator of this site? Confirm its status | Qingdao | China | Recruiting |
| Zhongshan Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.